IDENTIFYSENSORS BIOLOGICS PARTNERS WITH JABIL HEALTHCARE TO MANUFACTURE DIGITAL DIAGNOSTIC PLATFORM

IdentifySensors Biologics has partnered with Jabil (NYSE: JBL) to manufacture portable diagnostic devices that detect infections molecularly with accuracy exceeding PCR tests.

Rhea-AI Summary

IdentifySensors Biologics has partnered with Jabil (NYSE: JBL) to manufacture portable diagnostic devices that detect infections molecularly with accuracy exceeding PCR tests. The Check4® devices include a multiple-use electronic reader and single-use test cartridges, capable of identifying four infections from saliva in minutes. This technology, developed in collaboration with Purdue University, enables real-time monitoring of test results at a lower cost than traditional methods. The partnership aims to ensure high-quality production of this innovative testing solution.

Positive

• Partnership with Jabil enhances manufacturing capabilities for the Check4® platform.
• Check4® devices offer superior accuracy and lower costs compared to traditional PCR tests.
• Real-time monitoring of test results for businesses and organizations.
• Technological innovation allows for rapid detection of multiple infections.

Negative

• None.

Argus Session date unavailable

+0.04% session move Open Argus

Details

News Market Reaction – JBL

The recorded move for JBL in the trading session of this news was +0.04%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CLEVELAND, July 12, 2022 /PRNewswire/ -- IdentifySensors Biologics, a pathogen-detection platform technology company, has partnered with Jabil Inc. (NYSE: JBL), a global manufacturing solutions company, to develop processes for reliable robust manufacturing of portable devices that rapidly detect a wide range of infections at the molecular level with accuracy that is superior to PCR testing.

A new portable digital reader now detects multiple infections from saliva in minutes with PCR accuracy.

The small portable devices, branded Check4^®, consist of two main parts: 1) a multiple-use electronic reader about the size of a cell phone; and 2) single-use test cartridges that detect as many as four separate infections simultaneously. For example, a single cartridge can detect COVID, Influenza A, Influenza B and RSV – all from a single saliva sample. Results appear in minutes on a user's cell phone, at home or on the go.

The Check4^® platform represents a technological breakthrough, which electronically identifies sequence-specific genetic material of target pathogens. The electronic test produces a digital signal that is analyzed in the cloud in less than three minutes. Solid-state, digital selectively deposited electrodes enable almost instantaneous results without laboratory work, chemical reagents or amplification.

Businesses, governments and organizations can remotely monitor individual and group test results in real time for employees, customers and visitors with accuracy superior to the current gold-standard PCR test, but at a materially lower cost. The Check4^® test is positioned to replace PCR and antigen tests for symptomatic and asymptomatic screening.

The technology was developed by IdentifySensors Biologics in partnership with Purdue University, which helped commercialize the process. The technology and applications are secured through multiple patents.

"We are very pleased to work with Jabil," said Gregory Hummer, M.D., CEO and cofounder of IdentifySensors. "Jabil has the experience and bandwidth to ensure this testing platform is manufactured efficiently and effectively with the highest quality controls in the industry. They will be a great partner for us."

About IdentifySensors Biologics
IdentifySensors Biologics is a Cleveland-based pathogen-detection platform technology company focused on developing real-time pathogen detection capabilities. The company's technology has expanded into multiple industries and applications, such as diagnostics, food safety & sustainability, environmental monitoring and national security. For more information visit www.identifysensors.com

News Media Contact
Joe Mosbrook
mosbrook@acclaimllc.com
216-375-2141

View original content to download multimedia:https://www.prnewswire.com/news-releases/identifysensors-biologics-partners-with-jabil-healthcare-to-manufacture-digital-diagnostic-platform-301584457.html

SOURCE IdentifySensors Biologics

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is the partnership between Jabil and IdentifySensors Biologics about?

IdentifySensors Biologics has partnered with Jabil to manufacture portable diagnostic devices that detect infections with high accuracy.

What does the Check4® device do?

The Check4® device detects multiple infections from a single saliva sample and provides results in minutes.

How does the Check4® technology compare to PCR tests?

The Check4® technology is superior to PCR tests in terms of accuracy and lower costs for detecting infections.

When was the partnership between Jabil and IdentifySensors announced?

The partnership was announced on July 12, 2022.

What infections can the Check4® device detect?

The Check4® device can detect COVID, Influenza A, Influenza B, and RSV from one saliva sample.